| 人GLP-1类似物治疗2型糖尿病的研究进展 |
| |
| 引用本文： | 蒋筠,彭永德.人GLP-1类似物治疗2型糖尿病的研究进展[J].世界临床药物,2010,31(2):74-77,97. |
| |
| 作者姓名： | 蒋筠 彭永德 |
| |
| 作者单位： | 上海交通大学附属第一人民医院内分泌科,上海,200080 |
| |
| 摘 要： | 人胰高血糖素样肽1（GLP-1）类似物已成为新一代降糖药。无论是上市的艾塞那肽和利拉鲁肽，还是处于临床研究阶段的taspoglutide，均在2型糖尿病临床研究中取得显著成果，如有效降糖、减轻体重和减少低血糖发生等。同时，人GLP—1类似物潜在的益处与风险还有待进一步研究。
|
| 关 键 词： | 2型糖尿病 肠促胰素 胰高血糖素样肽1 类似物 |
Research progress of human GLP-1 analogues for type 2 diabetes |
| |
| JIANG Yun,PENG Yong-de.Research progress of human GLP-1 analogues for type 2 diabetes[J].WORLD CLINICAL DRUGS,2010,31(2):74-77,97. |
| |
| Authors: | JIANG Yun PENG Yong-de |
| |
| Institution: | Department of Endocrinology;Shanghai First People's Hospital;Shanghai Jiaotong University;Shanghai 200080;China |
| |
| Abstract: | Human glucagon-like peptide-1(GLP-1) analogues have become the new generation of hypoglycemic agents.Exenatide and liraglutide are already on the market.Taspoglutide is currently moving into phase 3 clinical trials.All of them have been proven effective in the treatment of type 2 diabetes,such as improvement in glycemia control,weight loss,a low incidence of hypoglycemia.Potential benefits and risks of human GLP-1 analogues require further study.This review described the progress on human GLP-1 analogues fo... |
| |
| Keywords: | type 2 diabetes mellitus incretin glucagon-like peptide-1 analogues |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
